Anteris Technologies announces $200M public offering to fund clinical growth

Anteris Technologies CEO Wayne Paterson joined Steve Darling from Proactive to announce that the company has launched a proposed underwritten public offering of $200 million of its common stock, subject to market and other customary conditions. In connection with the offering, Anteris also plans to grant the underwriters a 30-day option to purchase up to an additional $30 million of common stock at the public offering price. Paterson also confirmed that Anteris has entered into a private placement agreement with Medtronic plc, further strengthening the company’s balance sheet and strategic positioning. The net proceeds from the public offering, together with existing cash and cash equivalents and the proceeds from the private placement, are expected to support the next phase of the company’s growth and the continued execution of its clinical and operational strategy. The company intends to use the funds to advance the ongoing global pivotal trial of its DurAVR® Transcatheter Heart Valve for patients with severe aortic stenosis. The PARADIGM Trial is currently focused on patient recruitment and study execution, and represents a key step toward potential regulatory approval of the DurAVR® THV. In addition, Anteris plans to expand its manufacturing capabilities to support future commercialization. A portion of the proceeds is also expected to fund continued research and development activities at v2vmedtech, inc., while the remaining capital will be allocated to working capital and other general corporate purposes as determined by management from time to time. Anteris Technologies is a global structural heart company dedicated to the design, development, and commercialization of advanced medical devices aimed at restoring healthy heart function. Founded in Australia with a significant operational presence in Minneapolis, Minnesota, the company is science-driven and supported by a multidisciplinary team with deep expertise in structural heart disease. The company’s lead product, the DurAVR® THV, was developed in collaboration with leading interventional cardiologists and cardiac surgeons worldwide to treat aortic stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. Anteris believes the DurAVR® THV has the potential to offer meaningful clinical benefits for patients suffering from this serious condition. He also discussed recent clinical data presented at the London Valve conference, spotlighting a dramatic reduction in patient-prosthetic mismatch (PPM) rates with DurAVR compared to the market leader—3% versus 30%. #proactiveinvestors #anteristechnologiesglobalcorp #asx #avr #nasdaq #avr #PublicOffering #MedTech #StructuralHeart #DurAVR #TranscatheterValve #AorticStenosis #ClinicalTrials #PARADIGMTrial #MedicalDevices #HealthcareInnovation #BiotechNews #Cardiology #HeartHealth #LifeSciences